Curis' CFO mentioned a $10 million quarterly cash burn, extending cash runway to Q4 2025. CEO noted partner interest in NHL and AML programs. Development Officer reported dosing 13 PCNSL patients with emavusertib.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay